{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:24:41Z","timestamp":1783009481762,"version":"3.54.5"},"reference-count":15,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n \n Treatment for neuroblastoma with chemotherapy and [\n 131<\/jats:sup>\n I]MIBG can induce endocrine adverse effects, including thyroid disorders, gonadal insufficiency or short stature. Neuroblastoma can also be targeted at the somatostatin receptor, using [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE peptide receptor radionuclide therapy. Thus far no endocrine effects have been reported after [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE treatment in children.\n <\/jats:p>\n <\/jats:sec>\n \n Case presentation<\/jats:title>\n \n We report a first case of pituitary dysfunction, reflected as growth hormone deficiency and central hypothyroidism, following treatment with [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE for refractory neuroblastoma.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n We hypothesize that the GH and TSH deficiency in this case are caused by pituitary damage through binding of [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE to the somatostatin receptors in the pituitary gland. If [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE in the future becomes a more upfront treatment we strongly underline screening on pituitary dysfunction after exposure to [\n \n 177<\/jats:bold>\n <\/jats:sup>\n Lu]Lu-DOTATATE in childhood.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2025-0426","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:56:11Z","timestamp":1772664971000},"page":"617-621","source":"Crossref","is-referenced-by-count":0,"title":["Pituitary dysfunction in childhood after [\n 177<\/sup>\n Lu]Lu-DOTATATE therapy"],"prefix":"10.1515","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8735-5354","authenticated-orcid":false,"given":"Karen","family":"van Wessel","sequence":"first","affiliation":[{"name":"Wilhelmina Children\u2019s Hospital , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-9483","authenticated-orcid":false,"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht , The Netherlands"},{"name":"Division Imaging & Cancer , University Medical Center Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6185-5569","authenticated-orcid":false,"given":"Miranda P.","family":"Dierselhuis","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-5838","authenticated-orcid":false,"given":"Max M.","family":"van Noesel","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht , The Netherlands"},{"name":"Division Imaging & Cancer , University Medical Center Utrecht , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6773-6931","authenticated-orcid":false,"given":"Hanneke M.","family":"van Santen","sequence":"additional","affiliation":[{"name":"Wilhelmina Children\u2019s Hospital , Utrecht , The Netherlands"},{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026070215583359896_j_jpem-2025-0426_ref_001","doi-asserted-by":"crossref","unstructured":"Georgantzi, K, Tsolakis, AV, Stridsberg, M, Jakobson, A, Christofferson, R, Janson, ET. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer 2011;56:584\u20139. https:\/\/doi.org\/10.1002\/pbc.22913.","DOI":"10.1002\/pbc.22913"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_002","doi-asserted-by":"crossref","unstructured":"Whittle, SB, Smith, V, Doherty, E, Zhao, S, McCarty, S, Zage, PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther 2017;17:369\u201386. https:\/\/doi.org\/10.1080\/14737140.2017.1285230.","DOI":"10.1080\/14737140.2017.1285230"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_003","doi-asserted-by":"crossref","unstructured":"Fathpour, G, Jafari, E, Hashemi, A, Dadgar, H, Shahriari, M, Zareifar, S, et al.. Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma. Clin Nucl Med 2021;46:540\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000003577.","DOI":"10.1097\/RLU.0000000000003577"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_004","doi-asserted-by":"crossref","unstructured":"Sundquist, F, Georgantzi, K, Jarvis, KB, Brok, J, Koskenvuo, M, Rascon, J, et al.. A phase II trial of a personalized, dose-intense administration schedule of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk Neuroblastoma-LuDO-N. Front Pediatr 2022;10:836230. https:\/\/doi.org\/10.3389\/fped.2022.836230.","DOI":"10.3389\/fped.2022.836230"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_005","doi-asserted-by":"crossref","unstructured":"Teunissen, JJ, Krenning, EP, de Jong, FH, de Rijke, YB, Feelders, RA, van Aken, MO, et al.. Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging 2009;36:1758\u201366. https:\/\/doi.org\/10.1007\/s00259-009-1151-8.","DOI":"10.1007\/s00259-009-1151-8"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_006","doi-asserted-by":"crossref","unstructured":"Sundl\u00f6v, A, Sjogreen-Gleisner, K, Tennvall, J, Dahl, L, Svensson, J, Akesson, A, et al.. Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up. Neuroendocrinology 2021;111:344\u201353. https:\/\/doi.org\/10.1159\/000507761.","DOI":"10.1159\/000507761"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_007","doi-asserted-by":"crossref","unstructured":"Gains, JE, Bomanji, JB, Fersht, NL, Sullivan, T, D\u2019Souza, D, Sullivan, KP, et al.. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J\u00a0Nucl Med 2011;52:1041\u20137. https:\/\/doi.org\/10.2967\/jnumed.110.085100.","DOI":"10.2967\/jnumed.110.085100"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_008","doi-asserted-by":"crossref","unstructured":"van Iersel, L, Xu, J, Potter, BS, Conklin, HM, Zhang, H, Chemaitilly, W, et al.. Clinical importance of free thyroxine concentration decline after radiotherapy for pediatric and adolescent brain tumors. J\u00a0Clin Endocrinol Metab 2019;104:4998\u20135007. https:\/\/doi.org\/10.1210\/jc.2019-00539.","DOI":"10.1210\/jc.2019-00539"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_009","unstructured":"van Iersel, L, van Santen, HM, Zandwijken, GRJ, Zwaveling-Soonawala, N, Hokken-Koelega, ACS, van Trotsenburg, ASP. Low FT4 concentrations around the start of recombinant human growth hormone treatment: predictor of congenital structural hypothalamic-pituitary abnormalities? Horm Res Paediatr 2018;89:98\u2013107."},{"key":"2026070215583359896_j_jpem-2025-0426_ref_010","doi-asserted-by":"crossref","unstructured":"van Santen, HM, de Kraker, J, Vulsma, T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2005.02.036.","DOI":"10.1016\/j.ejca.2005.02.036"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_012","doi-asserted-by":"crossref","unstructured":"Dhouib, NG, Ben Khaled, M, Ouederni, M, Besbes, H, Kouki, R, Mellouli, F, et al.. Growth and endocrine function in Tunisian thalassemia major patients. Mediterr J Hematol Infect Dis 2018;10:e2018031.","DOI":"10.4084\/mjhid.2018.031"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_011","doi-asserted-by":"crossref","unstructured":"Gubbi, S, Al-Jundi, M, Auh, S, Jha, A, Zou, J, Shamis, I, et al.. Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy. Front Endocrinol (Lausanne) 2023;14:1275813. https:\/\/doi.org\/10.3389\/fendo.2023.1275813.","DOI":"10.3389\/fendo.2023.1275813"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_013","doi-asserted-by":"crossref","unstructured":"Ngim, CF, Lai, NM, Hong, JY, Tan, SL, Ramadas, A, Muthukumarasamy, P, et al.. Growth hormone therapy for people with thalassaemia. Cochrane Database Syst Rev 2020;5:CD012284. https:\/\/doi.org\/10.1002\/14651858.CD012284.pub2.","DOI":"10.1002\/14651858.CD012284.pub3"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_014","doi-asserted-by":"crossref","unstructured":"Moroz, V, Machin, D, Hero, B, Ladenstein, R, Berthold, F, Kao, P, et al.. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2020;67:e28359. https:\/\/doi.org\/10.1002\/pbc.28359.","DOI":"10.1002\/pbc.28359"},{"key":"2026070215583359896_j_jpem-2025-0426_ref_015","doi-asserted-by":"crossref","unstructured":"van Iersel, L, Mulder, RL, Denzer, C, Cohen, LE, Spoudeas, HA, Meacham, LR, et al.. Hypothalamic-pituitary and other endocrine surveillance among childhood cancer survivors. Endocr Rev 2022;43:794\u2013823. https:\/\/doi.org\/10.1210\/endrev\/bnab040.","DOI":"10.1210\/endrev\/bnab040"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0426\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:11:38Z","timestamp":1783008698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0426\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,15]]},"published-print":{"date-parts":[[2026,6,24]]}},"alternative-id":["10.1515\/jpem-2025-0426"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0426","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}